EUCTR2012-000537-39-DE进行中（未招募）不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject.
- •2. The subject was randomized into Study M11-793 and completed through Week 24 in that study.
- •3. With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG.
- •4. If male, the subject is surgically sterile (vasectomy), is sexually inactive, or is using a barrier method of birth control (condom) with spermicidal foam/gel/film/cream/suppository for the duration of the study and for 30 days following the last dose of study. However, if the male subject's partner has been postmenopausal for at least two years or is surgically sterile, then use of a barrier method of birth control is not required.
- •5. The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study.
- •6. The subject and caregiver must have sufficient visual, hearing and graphomotor skills to complete the study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 340
排除标准
- •1. The subject experienced an adverse event or abnormal finding during physical examination, vital signs, laboratory profile and/or ECG measurements in Study M11-793 that indicates the subject could become medically unstable during the current study.
- •2. The subject is currently taking or is expected to be prescribed any excluded medication without the approval of Abbott medical monitor.
- •3. The subject was noncompliant with donepezil or rivastigmine during Study M11-793 or is expected to discontinue these medications prior to conclusion of this study.
- •4. The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
- •5. The subject is currently enrolled in, or plans to participate in, another interventional study during the course of this trial.
- •6. The subject developed any significant medical or psychiatric condition that, in the opinion of the investigator, renders the subject an unsuitable candidate to participate in the study.
- •7. For any reason the investigator considers the subject to be an unsuitable candidate to receive ABT-126 or to participate in this study.
研究者
相似试验
进行中（未招募）
不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793Alzheimer's diseaseMedDRA version: 16.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2012-000537-39-GBAbbVie Deutschland GmbH & Co. KG400
进行中（未招募）
不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease: An Open-Label Extension Study for Subjects Completing Study M10-985.EUCTR2011-004780-75-GBAbbVie Deutschland GmbH & Co. KG400
进行中（未招募）
不适用
ong-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793MedDRA version: 14.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2012-000537-39-GRAbbott GmbH & Co. KG400
进行中（未招募）
1 期
ong-Term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855Cognitive deficits in schizophreniaMedDRA version: 17.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2012-005661-13-GBAbbVie Deutschland GmbH & Co. KG430
终止
2 期
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01690195AbbVie (prior sponsor, Abbott)343